Featured Research

from universities, journals, and other organizations

Discovering how stomach cancer spreads

Date:
November 13, 2012
Source:
University of Liverpool
Summary:
Scientists have found that the production of a protein that prevents the growth and spread of cancerous cells is impaired in patients with gastric cancer.

A cancer cell. Cancer of the stomach is the second most common cause of death due to malignant disease worldwide.
Credit: Image courtesy of University of Liverpool

Scientists at the University of Liverpool have found that the production of a protein that prevents the growth and spread of cancerous cells is impaired in patients with gastric cancer.

Cancer of the stomach is the second most common cause of death due to malignant disease worldwide. New research findings at Liverpool, however, could contribute to the development of future gastric cancer therapies by restoring the functions of a protein called, TGFβig-h3.

Development of future therapies

The protein is released by cells called myofibroblasts, which form part of the supporting tissue around cancer cells. The environment of myofibroblasts, blood vessels and other cell types, allows cancer to survive and can become as high as 70-90% of the total tumour mass.

Myofibroblasts are highly mobile cells that produce and release multiple substances that change cancer behaviour by altering their environment, leading to the growth and spread of cancerous cells. Scientists at Liverpool have now discovered that in tumours of advanced gastric cancer patients, the myofibroblasts decrease the release of a protein that would normally inhibit the growth and spread of the disease.

Long-term recovery

Professor Andrea Varro, from the University's Institute of Translational Medicine, explains "This protein normally acts as an anchor to link cells to proteins in the cancer cell environment restricting cancerous cells to the vicinity in which they have grown. This allows targeting of treatments to the area, but in advanced stages of the disease the effects of this protein are diminished, increasing the risk of the disease spreading to other parts of the body.

"We hope that this work will help develop future treatments that are based on restoring the functions of this protein, contributing to the long-term recovery of patients with this often fatal disease."


Story Source:

The above story is based on materials provided by University of Liverpool. Note: Materials may be edited for content and length.


Journal Reference:

  1. C. Holmberg, M. Quante, I. Steele, J. D. Kumar, S. Balabanova, C. Duval, M. Czepan, Z. Rakonczay, L. Tiszlavicz, I. Nemeth, G. Lazar, Z. Simonka, R. Jenkins, P. Hegyi, T. C. Wang, G. J. Dockray, A. Varro. Release of TGFig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression. Carcinogenesis, 2012; 33 (8): 1553 DOI: 10.1093/carcin/bgs180

Cite This Page:

University of Liverpool. "Discovering how stomach cancer spreads." ScienceDaily. ScienceDaily, 13 November 2012. <www.sciencedaily.com/releases/2012/11/121113122649.htm>.
University of Liverpool. (2012, November 13). Discovering how stomach cancer spreads. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2012/11/121113122649.htm
University of Liverpool. "Discovering how stomach cancer spreads." ScienceDaily. www.sciencedaily.com/releases/2012/11/121113122649.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins